The purpose of this study is to determine the efficacy of the combination of thalidomide and capecitabine in metastatic renal cell carcinoma and also to determine the safety of the combination.
Inclusion Criteria:- Able to comprehend and sign an IRB approved Informed consent
Willingness and ability to comply with the FDA-mandated S.T.E.P.S.® program. Male or female 18 years or older Willing to use contraception Pathologic diagnosis of renal cell carcinoma Bi-dimensionally measurable disease Evidence of disease progression prior to start of treatment Failed prior immunotherapy or unwilling/unable to receive prior immunotherapy Adequate hematologic data: ANC.1.5; platelets>100x10^9 Adequate renal function: Creatinine clearance .50cc Adequate liver function: Alkaline phos <3XULN AST/ALT <3XULN T.Bili <1.5XULN ECOG performance status 0-1 Exclusion Criteria:- Known brain metastases. Peripheral neuropathy. Pregnant and/ or lactating female. Unable to take a baby aspirin.
